Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders

被引:5
作者
Valdivia-Tangarife, Edgar R. [1 ]
Gamez-Nava, Jorge, I [1 ,2 ]
Cortes-Enriquez, Fernando [3 ]
Mireles-Ramirez, Mario A. [4 ]
Gonzalez-Lopez, Laura [1 ,2 ]
Saldana-Cruz, Ana M. [5 ]
Angel Macias-Islas, Miguel [6 ]
机构
[1] Univ Guadalajara, Ctr Univ Ciencias Salud CUCS, Farmacol, Guadalajara 44340, Jalisco, Mexico
[2] Univ Guadalajara, CUCS, Salud Publ, Guadalajara 44340, Jalisco, Mexico
[3] Inst Mexicano Seguro Social, Dept Neurol, Hosp Gen Reg 45, Guadalajara, Jalisco, Mexico
[4] Inst Mexican Seguro Social, Ctr Med Nacl Occidente, Unidad Alta Especialidad Med, Dept Neurol, Guadalajara, Jalisco, Mexico
[5] Univ Guadalajara, Inst Terapeut Expt & Clin, Dept Fisiol, CUSC, Cusc, Jalisco, Mexico
[6] Univ Guadalajara, Dept Neurociencias, Guadalajara 44340, Jalisco, Mexico
关键词
Risk Factors; Permanent Disability; Permanent visual disability; Permanent motor disability; Neuromielitis Optica Spectrum Disorders; PROGRESSION; ONSET;
D O I
10.1016/j.msard.2022.104114
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system. In NMOSD, a relapse results in increased disability. Objective: To assess risk factors associated with permanent disability (PD) in patients with neuromyelitis optica spectrum disorders (NMOSD). Methods: We evaluated 34 cases (who developed permanent disability) and 33 controls. The assessment included the following variables: sociodemographic data and characteristics of the disease. Logistic regression analysis was performed to adjust variables associated with PD. Results: fifty-one percent developed PD during follow-up; 15 (22%) developed permanent visual disability, 13 (19%) developed permanent motor disability and 6 (9%) were restricted to wheelchair. Factors associated with PD in the crude analysis were: age at onset >= 50 years (OR 3.95, 95% IC 1.12-13.94, p= 0.032), time from onset to diagnosis >= 12 months (OR 3.30, 95% IC 1.13-9.64, p= 0.029), time from onset to treatment >= 60 months (OR 4.16, 95% IC 1.03-16.85, p= 0.045), EDSS >= 4.0 at the first appointment (OR 3.21, 95% IC 1.18-8.76, p= 0.022) and severe relapses during disease evolution (OR 5.72, 95% IC 1.98-16.57, p= 0.001). Factors associated with PD in the adjusted analysis were: age at onset >= 50 years (OR 5.82, 95% IC 1.30-26.05, p= 0.021), time from onset to diagnosis >= 12 months (OR 5.43, 95% IC 1.47-20.08, p= 0.011) and severe relapses during disease evolution (OR 6.65, 95% IC 1.98-22.31, p= 0.002). Conclusion: Half of patients with NMOSD may develop PD during disease evolution. Age of onset >= 50 years, delay to diagnosis >= 12 months and initial EDSS >= 4.0 constitute the strongest risk factors for PD.
引用
收藏
页数:5
相关论文
共 30 条
  • [11] Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica
    Jiao, Yujuan
    Fryer, James P.
    Lennon, Vanda A.
    Jenkins, Sarah M.
    Quek, Amy M. L.
    Smith, Carin Y.
    McKeon, Andrew
    Costanzi, Chiara
    Iorio, Raffaele
    Weinshenker, Brian G.
    Wingerchuk, Dean M.
    Shuster, Elizabeth A.
    Lucchinetti, Claudia F.
    Pittock, Sean J.
    [J]. NEUROLOGY, 2013, 81 (14) : 1197 - 1204
  • [12] Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders
    Kim, Su-Hyun
    Hyun, Jae-Won
    Joung, AeRan
    Park, Eun Young
    Joo, Jungnam
    Kim, Ho Jin
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1902 - 1908
  • [13] Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
    Kitley, Joanna
    Leite, M. Isabel
    Nakashima, Ichiro
    Waters, Patrick
    McNeillis, Benjamin
    Brown, Rachel
    Takai, Yoshiki
    Takahashi, Toshiyuki
    Misu, Tatsuro
    Elsone, Liene
    Woodhall, Mark
    George, Jithin
    Boggild, Mike
    Vincent, Angela
    Jacob, Anu
    Fujihara, Kazuo
    Palace, Jacqueline
    [J]. BRAIN, 2012, 135 : 1834 - 1849
  • [14] Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy
    Ma, Xiaoyu
    Kermode, Allan G.
    Hu, Xueqiang
    Qiu, Wei
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [15] Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions
    Mealy, Maureen A.
    Mossburg, Sarah E.
    Kim, Su-Hyun
    Messina, Silvia
    Borisow, Nadja
    Lopez-Gonzalez, Reydmar
    Ospina, Juan Pablo
    Scheel, Michael
    Yeshokumar, Anusha K.
    Awad, Amine
    Leite, M. Isabel
    Arango, Jorge A. Jimenez
    Paul, Friedemann
    Palace, Jacqueline
    Kim, Ho Jin
    Levy, Michael
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 64 - 68
  • [16] Epidemiology of Neuromyelitis Optica in the United States A Multicenter Analysis
    Mealy, Maureen A.
    Wingerchuk, Dean M.
    Greenberg, Benjamin M.
    Levy, Michael
    [J]. ARCHIVES OF NEUROLOGY, 2012, 69 (09) : 1176 - 1180
  • [17] Immune memory and aging: an infinite or finite resource?
    Nikolich-Zugich, Janko
    Rudd, Brian D.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2010, 22 (04) : 535 - 540
  • [18] Optic neuromyelitis syndrome in Brazilian patients
    Papais-Alvarenga, RM
    Miranda-Santos, CM
    Puccioni-Sohler, M
    de Almeida, AMV
    Oliveira, S
    De Oliveira, CAB
    Alvarenga, H
    Poser, CM
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (04) : 429 - 435
  • [19] Worldwide Incidence and Prevalence of Neuromyelitis Optica A Systematic Review
    Papp, Viktoria
    Magyari, Melinda
    Aktas, Orhan
    Berger, Thomas
    Broadley, Simon A.
    Cabre, Philippe
    Jacob, Anu
    Kira, Jun-ichi
    Leite, Maria Isabel
    Marignier, Romain
    Miyamoto, Katsuichi
    Palace, Jacqueline
    Saiz, Albert
    Sepulveda, Maria
    Sveinsson, Olafur
    Illes, Zsolt
    [J]. NEUROLOGY, 2021, 96 (02) : 59 - 77
  • [20] What You Need to Know About AQP4, MOG, and NMOSD
    Prasad, Sashank
    Chen, John
    [J]. SEMINARS IN NEUROLOGY, 2019, 39 (06) : 718 - 731